ClinicalTrials.gg
RecruitingNCT06803680Updated Aug 24, 2026

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of BGB-B455 and Chemotherapy in Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by BeOne Medicines. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,055 studies in Neoplasm Metastasis with a site in United States — 347 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
564th of 1,864
90 · median 43
Started
2025
with 84 others
Phase 1
710 of 2,055
129 open now
Primary completion
2028-04
later than 380 of 541 live
Registered
1,914th of 2,055
by date

Among the 2,055 studies in Neoplasm Metastasis with a site in United States, this one is the 564th largest by planned enrollment of the 1,864 interventional ones that give a count, is one of 85 that started in 2025, is one of 710 in phase 1, reaches primary completion later than 380 of the 541 other live ones, and was the 1,914th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

347 of the 2,055 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,055 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors.

The main questions it aims to answer are:

  • What is the recommended dosing for BGB-B455?
  • What medical problems do participants have when taking BGB-B455?

The study has two parts:

  • Phase 1a: dose escalation and safety expansion
  • Phase 1b: dose expansion
Read the detailed description

Claudin proteins are cell proteins that can play an important role in how cancer starts and progresses. Because of its preferential expression in tumors compared to normal tissues, CLDN6 is an ideal tumor antigen to target for treatment. BGB-B455 is a bispecific antibody (BsAbs) that targets CLDN6 on tumor cells and the CD3 receptor on T cells, which may provide a CLDN6-dependent antitumor immune response in a more tolerable manner without undue systemic toxicity.

This new study will check how safe and helpful this potential anticancer drug is. In addition, this study will explore the recommended dosing level for BGB-B455. This drug will be tested by itself or in combination with investigator-selected chemotherapy in participants with selected solid tumors expressing the CLDN6 protein.

This study is an open label study, meaning that both you and your study doctor will know what study drug/treatment you are given. This study has two parts:

  • Phase 1a consists of a dose escalation part where increasing amounts of the study treatment are given to different dose cohorts, and a safety expansion part that will enroll additional participants at selected doses for further assessments.
  • Phase 1b (dose expansion) will enroll participants at the best dose found in Phase 1a to see if it helps people with certain solid tumors.

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • Claudin-6
  • CLDN6+
  • advanced or metastatic solid tumor
  • CD3
  • BsAb
  • bispecific antibody
  • CD3-BsAb
  • CLDN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced or , and unresectable solid tumors who have previously received standard systemic therapy for advanced or metastatic disease or for whom treatment is not available or not tolerated. Only participants with CLDN6+ high-grade OC (ie, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer) will be enrolled in dose escalation cohorts, starting from Protocol Amendment 3.0.
  • Agreement for collection of formalin-fixed paraffin-embedded (FFPE) tumor tissue for central CLDN6 testing and other biomarker assessments.
  • Tumor CLDN6 expression (CDLN6+) by central immunohistochemistry testing is required for certain cohorts.
  • ≥ 1 as assessed by v1.1.
  • Stable (ECOG) Performance Status of 0 or 1.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anticancer therapy, including chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin), targeted therapy, and antibody drug conjugates (ADCs) that are standard or agents (including herbal medicine or Chinese [or other country] patent medicines, ≤ 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug(s).
  • Palliative radiation treatment or other locoregional therapies ≤ 14 days before the first dose of study drug(s).
  • ≤ 28 days before the first dose of study drug(s). Vaccines for COVID-19 are allowed except for any live vaccine that may become available. Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.
  • Any major surgical procedure ≤ 28 days before the first dose of study drug(s).
  • History of prior ≥ Grade 3 cytokine release syndrome (CRS).
  • Participants with toxicities (because of prior anticancer therapy) that have not recovered to baseline or stabilized, except for adverse events not considered a likely safety risk (eg, alopecia, neuropathy, and specific laboratory abnormalities).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Phase 1a: Dose Escalation and Safety Expansion

    Sequential cohorts of increasing dose levels of BGB-B455 will be evaluated as monotherapy.

    Drug: BGB-B455

  • Experimental
    Phase 1b: Dose Expansion

    Recommended Dose(s) for Expansion (RDFE\[s\]) of BGB-B455 determined from Phase 1a as monotherapy or in combination with investigator-selected chemotherapy will be evaluated for selected indications based on emerging data.

    Drug: BGB-B455 · Drug: Chemotherapy

Interventions

  • DrugBGB-B455

    Planned doses administered on specified days per protocol.

  • DrugChemotherapy

    Administered in accordance with relevant local guidelines and/or prescribing information.

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with AEs and SAEs, including laboratory abnormalities, and AEs that meet protocol-defined dose-limiting toxicity (DLT) criteria or protocol-defined adverse events of special interest (AESI) criteria.

    Time frame: From the first dose of study drug(s) to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first; up to approximately 7 months

  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B455

    MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate. MAD is defined as the highest dose administered if MTD is not reached.

    Time frame: Approximately 1 month

  3. Phase 1a: RDFE of BGB-B455

    RDFE of BGB-B455 will be determined based upon the MTD or MAD.

    Time frame: Approximately 1 month

  4. Phase 1b: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR), as determined from tumor assessments by investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). CR and PR must be confirmed by repeat assessments.

    Time frame: Approximately 18 months

Secondary outcomes

  1. Phase 1a: ORR

    ORR is defined as the percentage of participants with best overall response of CR or PR, as determined from tumor assessments by investigator per RECIST v1.1. CR and PR must be confirmed by repeat assessments.

    Time frame: Approximately 18 months

  2. Phase 1a and 1b: Duration of Response (DOR)

    DOR is defined as the time from the first confirmed objective response to documented disease progression or death, whichever occurs first, as determined from tumor assessments by investigator per RECIST v1.1.

    Time frame: Approximately 18 months

  3. Phase 1a and 1b: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieve CR, PR, or stable disease, as determined from tumor assessments by investigator per RECIST v1.1.

    Time frame: Approximately 18 months

  4. Phase 1a and 1b: Time to Response (TTR)

    TTR is defined as the time from the date of the first administration of study drug to the first confirmed response, as determined from tumor assessments by investigator per RECIST v1.1.

    Time frame: Approximately 18 months

  5. Phase 1a and 1b: Serum concentrations of BGB-B455

    Time frame: Approximately 7 months

  6. Phase 1b: Progression-Free Survival (PFS)

    PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death, whichever occurs first, as determined from tumor assessments by investigator per RECIST v1.1.

    Time frame: Approximately 18 months

  7. Phase 1b: Number of participants with AEs

    Number of participants with AEs, including physical examinations, electrocardiograms (ECGs), and laboratory assessments as indicated.

    Time frame: From the first dose of study drug(s) to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first; up to approximately 7 months

  8. Phase 1a and 1b: Area under the concentration-time curve (AUC) of BGB-B455

    Time frame: Approximately 4 months

  9. Phase 1a and 1b: Maximum observed plasma concentration (Cmax) of BGB-B455

    Time frame: Approximately 4 months

  10. Phase 1a and 1b: Time to reach maximum observed plasma concentration (Tmax) of BGB-B455

    Time frame: Approximately 4 months

  11. Phase 1a and 1b: Trough Concentration (Ctrough) of BGB-B455

    Time frame: Approximately 7 months

  12. Phase 1a and 1b: Apparent clearance (CL) of BGB-B455

    Time frame: Approximately 4 months

  13. Phase 1a and 1b: Volume of distribution (Vd) of BGB-B455

    Time frame: Approximately 4 months

  14. Phase 1a and 1b: Accumulation Ratio of BGB-B455

    Time frame: Approximately 4 months

  15. Phase 1a and 1b: Terminal half-life (t1/2) of BGB-B455

    Time frame: Approximately 4 months

07

Study locations

10 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2028, 37 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 37 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Jan 31, 2025
StartActual
Mar 18, 2025
Primary completionEst.
Apr 29, 2028
CompletionEst.
Apr 29, 2028
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06803680
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jan 31, 2025
Start date
Mar 18, 2025
Primary completion
Apr 29, 2028 (estimated)
Completion
Apr 29, 2028 (estimated)
Last update
Aug 24, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
1.877.828.5568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion